In this issue of Pediatrics, Dasgupta-Tsinikas et al1 present several important issues faced by clinicians in selecting antibiotic therapy for infants and children with urinary tract infection (UTI) based on laboratory-reported culture results. The laboratory report provides the clinician with 2 important pieces of data: the minimum inhibitory concentration (MIC) of each antibiotic tested against the urine isolate and an interpretation of that MIC value, given as susceptible (S), intermediate (I), or resistant (R). The MIC at which an antibiotic/organism pair goes from S to nonsusceptible (that includes I and R), is the “breakpoint,” and differentiates lower MICs for an antibiotic/pathogen pair for which antibiotic treatment should be successful at standard antibiotic doses from higher MICs at which there is an increased risk of microbiologic failure. This reported breakpoint interpretation of the MIC is under the jurisdiction of the United States Food and Drug Administration (FDA) and is generally...
Skip Nav Destination
Article navigation
July 2022
Commentaries|
June 23 2022
Urinary Tract Infections Treated by Third-Generation Cephalosporins
John S. Bradley, MD
aRady Children’s Hospital San Diego, Division of Infectious Diseases, San Diego, California
bDepartment of Pediatrics, University of California San Diego School of Medicine, San Diego, California
Address correspondence to John S. Bradley, MD, 3020 Children’s Way, MC 5041, San Diego CA 92123. E-mail: jsbradley@health.ucsd.edu
Search for other works by this author on:
Address correspondence to John S. Bradley, MD, 3020 Children’s Way, MC 5041, San Diego CA 92123. E-mail: jsbradley@health.ucsd.edu
Pediatrics (2022) 150 (1): e2022056219.
Article history
Accepted:
April 11 2022
Connected Content
This is a commentary to:
Treatment and Epidemiology of Third-Generation Cephalosporin-Resistant Urinary Tract Infections
Citation
John S. Bradley; Urinary Tract Infections Treated by Third-Generation Cephalosporins. Pediatrics July 2022; 150 (1): e2022056219. 10.1542/peds.2022-056219
Download citation file:
0 Comments
Comments Icon
Comments (0)
Sign in
Don't already have an account? Register
Pay-Per-View Access
$25.00
461
Views
0
Citations